請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90203
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳忠仁 | zh_TW |
dc.contributor.advisor | Chung-Jen Chen | en |
dc.contributor.author | 廖順彬 | zh_TW |
dc.contributor.author | Shun-Ping Liao | en |
dc.date.accessioned | 2023-09-22T17:50:34Z | - |
dc.date.available | 2023-11-09 | - |
dc.date.copyright | 2023-09-22 | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2023-08-03 | - |
dc.identifier.citation | 1.陳忠仁教授. (2022).策略管理-競爭優勢與經營發展,
2.Abbott Laboratories. (2018-2022). Abbott Annual Report 3.Jim Collis. (2001). Good to Great (從A到A+) 4.Encyclopædia Britannica (大英百科全書) 5.Medical Nutrition International Industry. (2018). Better care through better nutrition: Value and effects of medical nutrition, A summary of the evidence base 6.Global Harmonization Task Force. (2005, May). Essential Principles of Safety and Performance of Medical Devices 7.Michael, E. Porter. (2008). On Competition (競爭論), 8.IQVIA. (2023, January). Global Use of Medicine, 2023 9.Global Market Insight. (2023, January). Clinical Nutrition Market - By Product (Infant Nutrition, Enteral Nutrition, Parenteral Nutrition), By Consumer (Pediatric, Adult), By Application (Cancer, Metabolic Disorders, Neurological Diseases), By Distribution Channel, By Dosage Formulation & Forecast, 2023-2032 10.PwC.(2021). In Vitra Diagnostic(IVD) Market Trends- Overview 11.Statista.(2023, June). Medical Devices – Worldwide 12.Global Monitor. (2020). Global In-Vitro Diagnostis Market Report (2020-2026) 13.Precedence Research .(2023, June). Cardiovascular Devices Market, Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 14.Precedence Research. (2023, August). Continuous Glucose Monitoring (CGM) Device Market, Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030, 15.Statista. (2021, October). Projected size of the glucose monitoring devices market worldwide from 2017 to 2027 16.Precedence Research. (2022, July). Neurostimulation Devices Market, Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2022-2030 17.World Health Organization. (2023, July). Global Health Expenditure Database 18.World Health Organization. (2022 October). Ageing and Health 19.Forbes. (2019, June). How Does Abbott's Established Pharmaceuticals Business Compare With Its Peers? 20.HTF Market Intelligence. (2022). Baby Drinks Market Size& Growth Outlook 2023-2028 report (HRFMI-1677) 21.Ken Research. (2022). Global Protein Supplement Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 report 22.Mordor Intelligence. (2022). Clinical Nutrition Market Size & Share Analysis- Growth Trend& forecasts(2023-2028) Report. 23.HTF Market Intelligence. (2021, August). Bakery& Cereals Market to See Major Growth by 2026 Myoplex, Glucerna, Pure Protein. 24.HTF Market Intelligence. (2018, August). Clinical Nutrition Products Market Is Booming Worldwide. 25.The Dark Report. (2022, August). 2021 Rankings of the World's Top 12 IVD Companies. 26.QSIGHT. (2021). Cardiology Medical Devices Share Shifts. 27.Medtech Insight.(2019, March). Neuromodulation Market: Innovation Brings High-Growth Rewards. 28.Seeking Alpha. (2021 August). Abbott Laboratories: High Single-Digit Long Run Revenue Growth. 29.Future Market Insights. (2023, Jun). Branded Generics Market Report 30.Abbott Laboratories. (2019). Abbott-Established-Pharmaceuticals-Fact-Sheet-2Q-2018 31.BMI Research; McKinsey analysis (2014). Accelerating access in emerging markets: Pharma’s next big launch challenge. 32.Harvard Business Review. (2006, October). "Emerging giants: Building world-class companies in developing countries". 33.Abbott Laboratories. (2023). Notice of Annual Meeting of Shareholders and Proxy Statement 2023 34.Brand Finance. (Jun 2023). Abbott Brand Value Report 35.Insight by Greyb. (2022 February). Abbott Patents – Key Insights and Stats. 36.Great Place To Work. (2022). 2021 global employee engagement study 37.Science Magazine. (2021 September). Abbott Again Recognized as One of the "Top Employers" in the Biotech and Pharmaceutical Industry. 38.Fortune. (2023 June). Best Companies to Work For® 2023 39.FAIR360. (2023). 2023 Top 50 Companies for Diversity. Retrieved from https://www.fair360.com/top-50-list/2023/ (Jun 07, 2023) 40.Fortune. (2023 June). World's Most Admired Companies, Fortune 1985-2023 41.Down Jones. (2022, December). A Decade of Sustainability Industry Leadership, 42.Sheri-Lynne Leskiw Parbudyal Singh, (2007),"Leadership development: learning from best practices",Leadership & Organization Development Journal, Vol. 28 Iss 5 pp. 444 – 464 43.Abbott Laboratories. (2023). Abbott-2022-Global-Sustainability-Report 44.Bozenhardt, Erich H.; Bozenhardt, Herman F. (18 October 2018). "Are You Asking Too Much From Your Filler?". Pharmaceutical Online (Guest column). VertMarkets. Archived from the original on 17 November 2020. 45.Viju Raghupathi. (2020). The influence of education on health: an empirical assessment of OECD countries for the period 1995–2015, Arch Public Health 78, 20 46.James E Bennett et.al., (2018). NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4, The LANCET, Volume 392, Issue 10152, P1072-1088, September 22, 2018, 47.Aylin Sertkaya, PhD1; Rebecca DeVries, ScD1; Amber Jessup, PhD2,3,4; et al., Estimated Cost of Developing a Therapeutic Complex Medical Device in the US,JAMA, 2022;5(9) 48.Joseph A. DiMasi, Henry G. Grabowski, Ronald W. Hansen (2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs". Journal of Health Economics, 47: 20–33. 49.Anette Küster , Nicole Adler. (2014). Pharmaceuticals in the environment: scientific evidence of risks and its regulation, Philos Trans R Soc Lond B Biol Sci, 2014 Nov 19; 369(1656) 50.Shahmoradi Mostafa, Mosadeghrad Ali Mohammad, Jaafaripooyan Ebrahim. (2021), Policies and Practices Catalyzing the Use of Generic Medicines: A Systematic Search and Review, Ethiop J Health Sci, 31(1): 167–178. 51.Anthony Okafor, (2019, June), European Scientific Journal, edition Vol.15, No.16 ISSN: 1857 – 7881 (Print) e - ISSN 1857- 7431 52.G. Nargund, (2009), Declining birth rate in Developed Countries: A radical policy re-think is required, Facts Views Vis Obgyn, 1(3): 191–193. | - |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/90203 | - |
dc.description.abstract | 過去幾年因為新冠病毒(COVID-19)的全球大流行,幾乎所有的國家都受到了巨大的衝擊與考驗,包括了對社會、政治、經濟等等各個層面的影響,而這些影響大多數是負面的,反觀醫療保健業在劇烈波動的總體經濟環境下,倒是表現出相對的產業穩健性。新冠病毒(COVID-19)的全球大流行對這個產業的成長甚至有推波助瀾的效果。
另外根據世界衛生組織的統計,80 歲或以上的人口數目預計在接下來的幾年將增加至目前的三倍,亦即由 2019 年的 1.43 億人,上升至 2050 年的 4.26 億人。所以即使是國際貨幣基金組織(IMF)預計接下來幾年全球經濟仍然會面臨許多的挑戰,例如持續性地通貨膨脹、地緣政治的不確定性及其他許多負面因素影響下,可能導致整體經濟發展在未來會趨緩,但不可諱言的是全球人口結構的轉變仍將在未來的幾十年帶動醫療保健行業的持續發展。 本研究試著鎖定一家在醫療保健行業中的全球企業,亦即美商亞培公司,希望透過一系列的觀察與分析去審視並評估該企業在過去五年,因為因應環境的改變而演化出來的企業成長策略、執行成效與結果,最終期待此一研究成果能成為其他生醫產業公司的仿效對象或借鏡。而這些一系列的分析包括了針對外部環境、競爭對手、產業環境、資源能力、事業組合、事業策略與成長策略的分析。 研究歸納以下結論: (一)、一個企業要持續成功需要從內部先審視起,首先要找到可以讓企業本身成為領先市場的關鍵事業,再則進行自我審視評估,進一步了解到企業本身是否對該事業充滿熱情及找出達成目標的驅動引擎。接下來則是執行企業成功三步驟,亦即有紀律的員工、有紀律的思考與有紀律的行動,缺一不可。就結果而論,目前該目標公司在這些環節上是確實的在扎實地執行並取得持續地成功。 (二)、一個企業的多角化經營可能有利於企業的未來發展,但是多角化經營存在著操作上的種種挑戰,包括官僚成本的增加、行政及後勤部門的支援多樣性及工作量的增加並導致管理上無法聚焦等,如何消彌企業多角化可能帶來的負面影響對企業至為關鍵。當然一個企業的多角化經營也有其好處包括,分散公司的投資風險、創造較大的內部資本市場、提高剩餘資源使用率或規避單一產業營運所帶來的風險,避免企業的盈餘波動影響到企業生存。而就結果論,個案公司至今在執行企業多角化的策略是非常成功的。而促成多角化經營成功最重要的關鍵因素應該與該企業歷任的CEO 是所謂的「第五級領導人」有關,該企業在內部的「第五級領導人」與領導團隊的帶領下,建立有紀律的團隊並採取有紀律的行動是絕對的相關的。 (三)、該企業在許多技術上透過「研發」與「創新」取得領先業界的技術與市占率,另外「購併」也是該企業達成差異化的重要策略之一。 (四)、因應外界快速變化的環境,事業策略應該保持彈性,迅速進行調整,以保持競爭力。 | zh_TW |
dc.description.abstract | Many trends already underway being accelerated by the impact of the pandemic including society, politics economic stability and healthcare system development. The healthcare industry has shown relative stability in the past fluctuating general economic environment. According to the statistics report from World Health Organization(WHO), the number of people aged 80 or above will grow triple in the next few years. The elder population will also raise up from current 143 million to 426 million by 2050. Even though the International Monetary Fund (IMF) predicts that global economy situation will face a lot of challenges including persistent inflation, geopolitical uncertainty and other unknow factors, but the shift in global demographic structure will become severe in the next few decades which is the main growth driver for healthcare industry development.
Abbott Laboratories is an international leading company in healthcare industry and the purpose of this study is to evaluate whether this subject company consistently success in the past five year despite a lot of challenges whatever external and internal. The methodology including to conduct a series of evaluation for external environment, key competitors’ comparison, resource capabilities, business portfolio and business strategy. Corporate strategy and implementation effectiveness will definitely be cooperated within this evaluation. The desired outcome could be a benchmark or learning for other biomedical companies in Taiwan. The conclusions of this research: (1). Abbott applies the Hedgehog concept sincerely and identify his key business focus. A simple, crystalline concept that flows from deep understanding about the intersection of three circles: a) what you are deeply passionate about, b) what you can be the best in the world at, and c) what best drives your economic or resource engine. The next action is to implement these three steps with seamless. Disciplined employees, disciplined thinking and disciplined action are indispensable. (2) Diversify is the key cooperate strategy of Abbott despite the foreseeable challenges including the increasing in bureaucratic costs and workload, the diversity of administrative and logistic support which leads to the inability to focus on management. However, diversify also has its benefits, including, diversify the company's investment risks, create a larger internal capital market, increase the utilization rate of remaining resources or avoid the risks brought by a single industrial operation, and avoid the huge fluctuations in the company's earnings from affecting the survival of the company, and the current operation of the company is diversified. The results demonstrates Abbott operates “ Diversify Strategy” is very successfully. One of the reasons to support this success is due to Abbott has great “ level-five leader” with leadership team, a “culture of disciple” should be the key factor in this success of diversification operation. (3) Abbott also takes the lead in various areas which helps this company to gain market share and take the leading position in several product portfolios and this achievement replies on extraordinary "R&D" and "innovation" in many technologies. In addition, "acquisition" is also one of the important cooperate strategies to achieve this goal. (4) Accelerate adaptability is a critical capability for the success of any change initiative, Abbott did it and it should be consistently existing internally. | en |
dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2023-09-22T17:50:34Z No. of bitstreams: 0 | en |
dc.description.provenance | Made available in DSpace on 2023-09-22T17:50:34Z (GMT). No. of bitstreams: 0 | en |
dc.description.tableofcontents | 口試委員會審定書 I
誌謝 II 中文摘要 III ABSTRACT V 目錄 VII 圖目錄 IX 表目錄 XII 第一章 緒論 1 1.1 研究背景與動機 3 1.2 研究目的與範圍 3 1.3 研究方法 3 第二章 文獻探討 5 2.1 產業定義 5 2.2 外部環境分析模型 8 2.3 企業內部分析模型 11 第三章 產業分析 16 3.1 產業總體環境 16 3.2 外部環境分析模型(PESTL)28 3.3 產業主要競爭者分析 (COMPETITORS ANALYSIS)34 3.4 外部環境產業分析模型-五力分析(FIVE FORCE ANALYSIS)46 第四章 個案公司分析 57 4.1 公司簡介 57 4.2 資源、能力與活動 71 4.3 事業組合分析 99 4.4 成長策略與作法 102 4.5 事業策略與作法 105 第五章 結論與建議 108 5.1 研究結論 108 5.2 研究建議 115 參考文獻 117 | - |
dc.language.iso | zh_TW | - |
dc.title | 從優秀到卓越 - 美商亞培公司與事業之發展策略研究 | zh_TW |
dc.title | From Good to Great - A Case Study of Abbott’s Corporate and Business Strategy | en |
dc.type | Thesis | - |
dc.date.schoolyear | 111-2 | - |
dc.description.degree | 碩士 | - |
dc.contributor.oralexamcommittee | 詹文男;陳宗權 | zh_TW |
dc.contributor.oralexamcommittee | Wen-Nan Tsan;Tzong-Chyuan Chen | en |
dc.subject.keyword | 醫療保健業,成長策略分析,多角化經營, | zh_TW |
dc.subject.keyword | healthcare industry,growth strategy analysis,diversification, | en |
dc.relation.page | 119 | - |
dc.identifier.doi | 10.6342/NTU202302385 | - |
dc.rights.note | 未授權 | - |
dc.date.accepted | 2023-08-07 | - |
dc.contributor.author-college | 進修推廣學院 | - |
dc.contributor.author-dept | 生物科技管理碩士在職學位學程 | - |
顯示於系所單位: | 生物科技管理碩士在職學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf 目前未授權公開取用 | 3.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。